Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
about
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-AnalysisLymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysisTumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysisPrognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysisPrognostic role of survivin in bladder cancer: a systematic review and meta-analysisPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.Clinical outcomes and correlates of TP53 mutations and cancer.Poor survival with wild-type TP53 ovarian cancer?Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.Prognostic biomarkers in ovarian cancer.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.Hippo pathway effector Yap is an ovarian cancer oncogene.Utilisation of search filters in systematic reviews of prognosis questions.HER2 expression in gastric and oesophageal cancer: a meta-analytic reviewPrognostic significance of lymphovascular invasion in radical cystectomy on patients with bladder cancer: a systematic review and meta-analysis.Extracapsular Extension of Pelvic Lymph Node Metastasis is an Independent Prognostic Factor in Bladder Cancer: A Systematic Review and Meta-analysis.Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.Prognostic significance of matrix metalloproteinase 7 immunohistochemical expression in colorectal cancer: a meta-analysis.Microvascular invasion as a prognostic indicator in renal cell carcinoma: a systematic review and meta-analysis.Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma.Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinomaPrognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis.BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls.Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma.Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review.Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis.High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancerThe relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.Intraoperative imaging in ovarian cancer: fact or fiction?Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
P2860
Q26748691-9D84A683-081C-4169-AB86-41F53DEB6FF3Q26997893-97CB5E88-4536-40A3-82D9-DFD5BBB3BE97Q27024810-9C6CA9AE-A159-424E-B332-36173E9F6203Q27027981-19615281-DD5C-4E23-BB69-F3A0D755C4BDQ27028122-274921D3-8BDF-4700-A195-B72051D2CE9AQ30365539-66928314-8E40-435F-AEBA-C749898EBF72Q33354953-3D3D147C-07DC-4576-85A2-66326B3C9032Q33395016-072AA168-89C3-4911-A9BC-2A28F0E42DE6Q33693838-B10E4065-131D-46D2-807D-E117A70752D3Q33761535-360F7FB3-C3BF-4AE7-B4A5-37EF3F86B2DEQ33779227-BF012241-6B35-46A5-845F-8CEAB4FBD4CBQ33960748-4ABF50CB-D396-4276-91BE-CEF538B67F29Q34086636-D16985B9-EDCD-4957-93D2-F8FE2F56FFE5Q34103978-7E24CD7B-F454-4953-B1A3-663B7C1C0D4BQ34188723-BABB9A04-F8E8-41EC-AAF0-918538B84DF4Q34267908-CA683F82-39D4-4FD9-A394-CD227D910C7EQ34486542-0EBEDA41-1B95-4A0D-A137-1F4D75E734DBQ35029025-3E089A20-3F80-40EE-81BD-17DB86579C2DQ35106939-EB4A4BFA-CCD8-4D72-B731-4E9151EEC912Q35547533-9048CFDB-8F59-48A7-804A-686C36B4DBF4Q35558111-DD2B6E41-9B48-4AC3-A8B7-7A52052C02AAQ35623109-B88FEF1F-E709-452F-8563-9CA29F0202B6Q35643502-4B9E756F-1342-46EF-AF38-C3EF0833BF7DQ35778887-15BA404A-FE1D-4410-ADD2-7C8F94783B1DQ35917703-2E0D50F6-A7E9-438F-BABC-339B82AAC445Q35996897-7F5EE26C-F197-497B-AA1D-36C1187B00ABQ36037099-FF89A4D1-A9E0-4D2C-86A2-0FB9666E40D8Q36135842-3E0669C1-1A61-4A57-9BFD-4775AAE42C24Q36207059-2BE0689B-5F44-49B2-9973-7CDDB40BA8F4Q36224562-BCAC1DB4-E925-4985-8AB5-37A6D263DB2CQ36288013-D35105FF-7B11-44AD-A952-464BC69A359AQ36397375-590E43E1-005A-400A-A05B-2571A9202525Q36504170-256ED1D1-A0B7-4407-9C76-7335FAB71554Q36571442-56F6F2EA-9158-494C-9E3E-B7005055C4E7Q36910793-4E3B5B57-59E7-4CD3-9BBD-30E67D048EC9Q36979335-6EB9D2C0-8036-4E0E-8271-D865CFD52B94Q37149571-620B5DD0-5AFE-4F93-A661-3D2CA28D6C08Q37328373-08C3547F-7F41-43A8-9586-8920ED50330EQ37388203-8E68E785-227C-4D09-AEDD-5A5E4E447541Q37620902-1C81BDF8-71D8-49D7-BAF5-A7241976B7E5
P2860
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modest effect of p53, EGFR and ...... varian cancer: a meta-analysis
@en
Modest effect of p53, EGFR and ...... arian cancer: a meta-analysis.
@nl
type
label
Modest effect of p53, EGFR and ...... varian cancer: a meta-analysis
@en
Modest effect of p53, EGFR and ...... arian cancer: a meta-analysis.
@nl
prefLabel
Modest effect of p53, EGFR and ...... varian cancer: a meta-analysis
@en
Modest effect of p53, EGFR and ...... arian cancer: a meta-analysis.
@nl
P2093
P2860
P356
P1476
Modest effect of p53, EGFR and ...... varian cancer: a meta-analysis
@en
P2093
A G J van der Zee
A P G Crijns
E G E de Vries
G H de Bock
P de Graeff
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605112
P407
P577
2009-06-09T00:00:00Z
P5875
P6179
1034014806